These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25938046)

  • 41. Should We Stop Treating Patients With Eplerenone for Chronic CSCR? Commentary on the VICI Trial.
    Daugirdas SP; Bheemidi AR; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2021 Jun; 52(6):308-310. PubMed ID: 34185584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy.
    Zola M; Daruich A; Matet A; Mantel I; Behar-Cohen F
    Br J Ophthalmol; 2019 Aug; 103(8):1184-1189. PubMed ID: 30355720
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study.
    Pitcher JD; Witkin AJ; DeCroos FC; Ho AC
    Br J Ophthalmol; 2015 Jun; 99(6):848-52. PubMed ID: 25595177
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Visual and Anatomical Outcomes of Spironolactone Therapy in Patients with Chronic Central Serous Chorioretinopathy.
    Falavarjani KG; Amirsardari A; Habibi A; Eshaghi A; Bakhti S; Aghdam KA
    J Ophthalmic Vis Res; 2017; 12(3):281-289. PubMed ID: 28791061
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY.
    Ghadiali Q; Jung JJ; Yu S; Patel SN; Yannuzzi LA
    Retina; 2016 Mar; 36(3):611-8. PubMed ID: 26405766
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis.
    Kapoor KG; Wagner AL
    Ophthalmic Res; 2016; 56(1):17-22. PubMed ID: 26982318
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BASELINE SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AS A PREDICTOR OF VISUAL OUTCOME AND RECURRENCE FOR CENTRAL SEROUS CHORIORETINOPATHY.
    Lee H; Lee J; Chung H; Kim HC
    Retina; 2016 Jul; 36(7):1372-80. PubMed ID: 26702841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR).
    Herold TR; Rist K; Priglinger SG; Ulbig MW; Wolf A
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):221-229. PubMed ID: 27475933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report.
    Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S
    J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Response of central serous chorioretinopathy evaluated by multimodal retinal imaging.
    Sacconi R; Baldin G; Carnevali A; Querques L; Rabiolo A; Marchini G; Bandello F; Querques G
    Eye (Lond); 2018 Apr; 32(4):734-742. PubMed ID: 29303152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
    Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME
    Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined Topical Anti-inflammatory and Oral Acetazolamide in the Treatment of Central Serous Chorioretinopathy.
    Wuarin R; Kakkassery V; Consigli A; Roquelaure D; Papanastasiou A; Schutz JS; Thumann G; Chronopoulos A
    Optom Vis Sci; 2019 Jul; 96(7):500-506. PubMed ID: 31274738
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Central serous chorioretinopathy induced by drugs metabolized by cytochrome P450 3A4.
    Morawski K; Klonowska A; Kubicka-Trzaska A; Woron J; Romanowska-Dixon B
    J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32776913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Choriocapillaris Reperfusion in Resolved Chronic Central Serous Chorioretinopathy Treated with Eplerenone: Long-Term Effects on the Fellow Eye.
    Viggiano P; Boscia G; Borrelli E; Toto L; Grassi MO; Evangelista F; Giancipoli E; Alessio G; Boscia F
    Ophthalmol Ther; 2023 Dec; 12(6):3199-3210. PubMed ID: 37747638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.
    Bousquet E; Beydoun T; Rothschild PR; Bergin C; Zhao M; Batista R; Brandely ML; Couraud B; Farman N; Gaudric A; Chast F; Behar-Cohen F
    Retina; 2015 Dec; 35(12):2505-15. PubMed ID: 26017871
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Significant Visual Impairment after Short-Lasting Central Serous Chorioretinopathy.
    Gawęcki M; Grzybowski A; Pompein-Batkiewicz M
    Case Rep Ophthalmol; 2022; 13(3):678-685. PubMed ID: 36742018
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Navigated laser photocoagulation in patients with non-resolving and chronic central serous chorioretinopathy.
    Müller B; Tatsios J; Klonner J; Pilger D; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1581-1588. PubMed ID: 29876733
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Naseripour M; Falavarjani KG; Sedaghat A; Moghaddam AK; Nasserisina S; Alemzadeh SA
    J Ophthalmic Vis Res; 2016; 11(1):66-9. PubMed ID: 27195088
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
    Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R
    Am J Ophthalmol; 2019 Feb; 198():80-87. PubMed ID: 30308202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.